Farallon Capital Management LLC Has $18.38 Million Stock Holdings in Savara Inc (NASDAQ:SVRA)

Farallon Capital Management LLC grew its holdings in shares of Savara Inc (NASDAQ:SVRA) by 90.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,560,000 shares of the company’s stock after buying an additional 2,165,701 shares during the quarter. Farallon Capital Management LLC’s holdings in Savara were worth $18,377,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. DRW Securities LLC purchased a new stake in shares of Savara in the second quarter worth approximately $62,000. Profund Advisors LLC bought a new stake in shares of Savara in the 2nd quarter worth $105,000. XTX Topco Ltd lifted its position in shares of Savara by 289.1% during the second quarter. XTX Topco Ltd now owns 41,059 shares of the company’s stock valued at $165,000 after purchasing an additional 30,508 shares in the last quarter. ClariVest Asset Management LLC boosted its holdings in Savara by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company’s stock worth $1,034,000 after purchasing an additional 7,170 shares during the last quarter. Finally, Choreo LLC purchased a new stake in Savara in the 2nd quarter valued at about $59,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

NASDAQ SVRA opened at $4.61 on Tuesday. The company has a market cap of $637.05 million, a PE ratio of -12.46 and a beta of 0.97. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm’s 50-day simple moving average is $4.38 and its two-hundred day simple moving average is $4.48. Savara Inc has a 52 week low of $3.12 and a 52 week high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Research analysts predict that Savara Inc will post -0.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim upped their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Oppenheimer upped their price objective on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Savara in a research report on Wednesday, August 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $11.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.